Timepoint | Enrollment allocation | Treatment period | Follow-up | |||||
---|---|---|---|---|---|---|---|---|
−1 week | 0 week | 1 week | 2 week | 3 week | 4 week | 8 week | 12 week | |
Enrolment | ||||||||
 Eligibility screen | X |  |  |  |  |  |  |  |
 Baseline | X |  |  |  |  |  |  |  |
 Informed consent | X |  |  |  |  |  |  |  |
 Randomization | X |  |  |  |  |  |  |  |
 Medical history | X |  |  |  |  |  |  |  |
 Merger disease | X |  |  |  |  |  |  |  |
 Allocation |  | X |  |  |  |  |  |  |
Interventions | ||||||||
 Group A |  |  | X | X | X | X | X | X |
 Group B |  |  | X | X | X | X | X | X |
 Group C |  |  | X | X | X | X | X | X |
 Group D |  |  | X | X | X | X | X | X |
Assessments | ||||||||
 WOMAC |  | X |  |  |  | X | X | X |
 VAS |  | X |  |  |  | X | X | X |
 AIMF2-SF |  | X |  |  |  | X | X | X |
 BAI |  | X |  |  |  | X | X | X |
 BDI |  | X |  |  |  | X | X | X |
 CEQ |  | X |  |  |  |  |  |  |
 Adverse events |  | X | X | X | X | X | X | X |